Enhanced immune effector cells and use thereof
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Ryan Bjordahl, Jode Goodridge, Tom Tong Lee
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Claims22
A cell or a population thereof, wherein
- (i) the cell is an NK cell obtained from differentiating a human induced pluripotent cell (iPSC), a human clonal iPSC, or a human iPSC cell line cell;
- and
- (ii) the cell comprises a CD38 knockout.
A cell or a population thereof, wherein
- (i) the cell comprises a CD38 knockout;
- (ii) the cell is (a) a human NK cell or human T cell;
- and (b) is obtained from differentiating a human induced pluripotent stem cell (iPSC), a human clonal iPSC, or a human iPSC cell line cell;
- and
- (iii) the cell (A) is in a composition comprising one or more checkpoint inhibitors, or (B) expresses one or more checkpoint inhibitors.
A population of cells, wherein:
- (i) the cells comprise a CD38 knockout;
- (ii) the cells are human hematopoietic cells obtained from differentiating human induced pluripotent cells (iPSCs), human clonal iPSCs, or human induced pluripotent stem cell line cells;
- and
- (iii) the population of cells comprises a longer average telomere length in comparison to their native counterpart cells obtained from peripheral blood, umbilical cord blood, or other donor blood.
Dependencies are inferred from the claim text.